国产创新药持续发力,AD治疗领域将迎来新突破

制药网
Mar 09

特应性皮炎(AD)是常见的慢性炎症性皮肤病,全球患者基数庞大,约有20%的儿童和7-14%的成人患有AD。AD虽不致命,但反复发作的剧烈瘙痒与皮损,对患者睡眠、心理与生活质量造成长期沉重负担,药物市场需求巨大。有数据显示,2024年全球AD药物市场规模约135–140亿美元,2025年已突破159亿美元。面对这一广阔的药物市场需求,国内药企正在积极加快研发的脚步。在AD药物研发中,IL-4R(...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10